Publications by authors named "R Canevari"
Article Synopsis
- Hepatic fibrosis involves excessive collagen buildup in the liver, affecting its normal function and structure.
- The study shows that using human amniotic membrane (AM) as a patch on the liver significantly reduces collagen levels in a rat model of biliary fibrosis.
- Results indicated that AM treatment increased the expression of matrix metalloproteinase 12 (MMP12), which helps lower collagen accumulation, suggesting a potential therapeutic role for AM in treating liver fibrosis.
Article Synopsis
- - The study analyzed the long-term effectiveness of mepolizumab in severe asthma patients, focusing on reducing exacerbations and steroid dependence over three years.
- - Results showed a significant decrease in exacerbations from 84.6% in the first year to 90% and 95% in the subsequent years, along with a reduction in steroid dependency from 54% to just 6%.
- - Additionally, patients with nasal polyps experienced a 49% decrease in symptoms measured by the SNOT-22 scale, confirming mepolizumab's long-term benefits in an actual clinical setting.
Omalizumab is a biological drug targeting circulating IgE, approved for use in allergic asthma, chronic spontaneous urticaria, and recently for chronic rhinosinusitis with nasal polyps, with good efficacy in all these settings. Some concerns about omalizumab safety have been raised as its use has been recently linked to potential increased cancer risk. Nevertheless, literature evidence does not support this statement, and clinical studies and evidence from real-world registries and surveillance analysis have consistently reported drug safety.
View Article and Find Full Text PDFBackground: Intraoperative intraorbital bleeding is a rare but potentially catastrophic event that can lead even to blindness, if not treated promptly. The goal of surgery is to quickly reduce intraorbital pressure thus restoring normal visual function. Aim of our work is to propose a practical algorithm helping the surgeon in the setting of this critical event.
View Article and Find Full Text PDFThe new indications for biologicals in type 2 diseases: perspectives.
Curr Opin Allergy Clin Immunol
December 2022
Purpose Of Review: To provide a literature review of what is on the market and under study for some diseases treated with drugs targeting type 2 (T2) inflammation.
Recent Findings: Literature data have shown that drugs targeting type 2 inflammation are effective in asthma and nasal polyposis, conditions for which they are on the market, and have promising expectations in the case of eosinophilic esophagitis, especially using anti-IL-5/IL-5 receptor and IL-4 receptor antibodies, while concerning eosinophilic granulomatosis with polyangitis (EGPA), mepolizumab (MEP) was approved by FDA and EMA as a drug for the treatment of this condition because of the promising results obtained in trials and in real life.
Summary: The use of these drugs is certainly an important achievement in the treatment of complex diseases such as those mentioned above, which are too often orphaned from innovative treatments and limited to the use of immunosuppressants and systemic corticosteroid for their control.